intravesical instillation with HA-CS

ApprovedSmall molecule

UUniversity Hospital, Basel, Switzerland

intravesical instillation with HA-CS is one of 18 small molecule programs targeting Recurrent urinary tract infections. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent Urinary Tract InfectionsActive, not recruiting

Recurrent Urinary Tract InfectionsApproved

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Recurrent Urinary Tract Infections

#DrugCompanyPhaseTrials

Monurol

MMeitheal

Approved

1 2

Merrem

BB. Braun Medical Inc.

Approved

—3

Avycaz

PPhiladelphia Eye Associates

Approved

—4

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Estrace

1 6

Intrarosa

Alnylam Pharmaceuticals

Phase 3

1 7

Vagifem

Novo Nordisk

Approved

1 8

Trimethoprim/sulfamethoxazole

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 3

1 9

Mannose

UUniversity of Colorado, Denver

Approved

1 10

ESTRING

UUniversity of California, San Francisco

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Recurrent urinary tract infections1 trial

Alternative Prophylaxis in Female Recurrent Urinary Tract Infections

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT04095572·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for intravesical instillation with HA-CS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — intravesical instillation with HA-CS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for intravesical instillation with HA-CS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Basel, Switzerland company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity Hospital, Basel, Switzerland

intravesical instillation with HA-CS

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Recurrent urinary tract infections1 trial

References

Drug Info

Quick Facts

Related News